Antibody response to COVID-19 booster vaccine in rituximab-treated patients with anti-neutrophil cytoplasmic antibody-associated vasculitis.
作者信息
Kant Sam, Azar Antoine, Geetha Duvuru
机构信息
Division of Nephrology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Division of Allergy and Immunology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
出版信息
Kidney Int. 2022 Feb;101(2):414-415. doi: 10.1016/j.kint.2021.11.012. Epub 2021 Nov 22.
Abstract
摘要
相似文献
1
Antibody response to COVID-19 booster vaccine in rituximab-treated patients with anti-neutrophil cytoplasmic antibody-associated vasculitis.利妥昔单抗治疗的抗中性粒细胞胞浆抗体相关性血管炎患者对新冠病毒加强疫苗的抗体反应
Kidney Int. 2022 Feb;101(2):414-415. doi: 10.1016/j.kint.2021.11.012. Epub 2021 Nov 22.
2
Impact of rituximab on humoral response to COVID-19 booster vaccine and antibody kinetics in patients with anti-neutrophil cytoplasmic antibody vasculitis.利妥昔单抗对抗中性粒细胞胞浆抗体血管炎患者针对新冠病毒加强疫苗的体液反应及抗体动力学的影响
Kidney Int. 2021 Nov;100(5):1124-1127. doi: 10.1016/j.kint.2021.08.020. Epub 2021 Sep 7.
3
COVID-19 and ANCA-associated vasculitis: recommendations for vaccine preparedness and the use of rituximab.2019冠状病毒病与抗中性粒细胞胞浆抗体相关性血管炎：疫苗接种准备及利妥昔单抗使用建议
Nephrol Dial Transplant. 2021 Aug 27;36(9):1758-1760. doi: 10.1093/ndt/gfab174.
4
Timing of rituximab and immunoglobulin level influence the risk of death for COVID-19 in ANCA-associated vasculitis.利妥昔单抗的使用时机和免疫球蛋白水平会影响抗中性粒细胞胞浆抗体相关性血管炎患者感染新型冠状病毒肺炎后的死亡风险。
Rheumatology (Oxford). 2021 Jul 1;60(7):3476-3477. doi: 10.1093/rheumatology/keab175.
5
The COVID-19 pandemic and ANCA-associated vasculitis - reports from the EUVAS meeting and EUVAS education forum.COVID-19 大流行与抗中性粒细胞胞浆抗体相关性血管炎——EUVAS 会议和 EUVAS 教育论坛的报告。
Autoimmun Rev. 2021 Dec;20(12):102986. doi: 10.1016/j.autrev.2021.102986. Epub 2021 Oct 28.
6
Mild COVID-19 in ANCA-associated vasculitis treated with rituximab.利妥昔单抗治疗抗中性粒细胞胞浆抗体相关性血管炎中的轻度新型冠状病毒肺炎
Ann Rheum Dis. 2021 Jun;80(6):e99. doi: 10.1136/annrheumdis-2020-218246. Epub 2020 Aug 7.
7
Myeloperoxidase anti-neutrophil cytoplasmic antibody positive optic perineuritis after mRNA coronavirus disease-19 vaccine.新型冠状病毒病19 mRNA疫苗接种后髓过氧化物酶抗中性粒细胞胞浆抗体阳性视神经周围炎
QJM. 2021 Dec 20;114(10):737-738. doi: 10.1093/qjmed/hcab227.
8
Expert Perspective: Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.专家视角：抗中性粒细胞胞浆抗体相关性血管炎的治疗。
Arthritis Rheumatol. 2022 Aug;74(8):1305-1317. doi: 10.1002/art.42114. Epub 2022 Jun 20.
9
[Should patients with ANCA-associated vasculitis undergoing maintenance therapy with rituximab receive cotrimoxazole prophylaxis?].接受利妥昔单抗维持治疗的抗中性粒细胞胞浆抗体相关性血管炎患者是否应接受复方新诺明预防？
Z Rheumatol. 2024 Mar;83(2):122-124. doi: 10.1007/s00393-023-01469-5. Epub 2024 Jan 25.
10
Rituximab versus cyclophosphamide for remission induction in active, severe antineutrophil cytoplasmic antibody-associated vasculitis: comment on the article by Chung et al.利妥昔单抗与环磷酰胺用于诱导活动性重症抗中性粒细胞胞浆抗体相关性血管炎缓解：对Chung等人文章的评论
Arthritis Rheumatol. 2022 Mar;74(3):544-545. doi: 10.1002/art.42002. Epub 2022 Jan 18.
引用本文的文献
1
Two Decades Rituximab Therapy in Anti-Neutrophil Cytoplasmic Antibody Associated Vasculitis.利妥昔单抗治疗抗中性粒细胞胞浆抗体相关性血管炎二十年
Curr Drug Targets. 2025;26(2):73-87. doi: 10.2174/0113894501323529240910015912.
2
Microfluidic antibody profiling after repeated SARS-CoV-2 vaccination links antibody affinity and concentration to impaired immunity and variant escape in patients on anti-CD20 therapy.反复接种 SARS-CoV-2 疫苗后微流控抗体分析显示，在接受抗 CD20 治疗的患者中，抗体亲和力和浓度与免疫受损和变异逃逸有关。
Front Immunol. 2024 Jan 8;14:1296148. doi: 10.3389/fimmu.2023.1296148. eCollection 2023.
3
BA.1/BA.5 Immunogenicity, Reactogenicity, and Disease Activity after COVID-19 Vaccination in Patients with ANCA-Associated Vasculitis: A Prospective Observational Cohort Study.COVID-19 疫苗接种后抗中性粒细胞胞质抗体相关性血管炎患者的 BA.1/BA.5 免疫原性、反应原性和疾病活动情况：一项前瞻性观察性队列研究。
Viruses. 2023 Aug 21;15(8):1778. doi: 10.3390/v15081778.
4
Managing Immunosuppression in Vasculitis Patients in Times of Coronavirus Disease 2019.COVID-19 时期血管炎患者的免疫抑制管理。
Rheum Dis Clin North Am. 2023 Aug;49(3):695-711. doi: 10.1016/j.rdc.2023.03.007. Epub 2023 Mar 14.
5
Efficacy and safety of mRNA and AstraZeneca COVID-19 vaccines in patients with autoimmune rheumatic diseases: A systematic review.mRNA 和阿斯利康 COVID-19 疫苗在自身免疫性风湿病患者中的疗效和安全性：一项系统评价。
Vaccine. 2023 Jun 13;41(26):3801-3812. doi: 10.1016/j.vaccine.2023.05.048. Epub 2023 May 22.
6
B Cell Reconstitution is Associated With COVID-19 Booster Vaccine Responsiveness in Patients Previously Seronegative Treated With Rituximab.B 细胞重建与 COVID-19 加强疫苗在先前接受利妥昔单抗治疗且血清阴性的患者中的反应性相关。
J Rheumatol. 2023 Mar;50(3):420-425. doi: 10.3899/jrheum.220475. Epub 2022 Dec 15.
7
The Four Ws of the Fourth Dose COVID-19 Vaccines: Why, Who, When and What.第四剂新冠疫苗的四个W：为何、何人、何时及何种。
Vaccines (Basel). 2022 Nov 14;10(11):1924. doi: 10.3390/vaccines10111924.
8
Booster COVID-19 Vaccines for Immune-Mediated Inflammatory Disease Patients: A Systematic Review and Meta-Analysis of Efficacy and Safety.免疫介导性炎症疾病患者的新冠病毒加强疫苗：疗效与安全性的系统评价和荟萃分析
Vaccines (Basel). 2022 Apr 22;10(5):668. doi: 10.3390/vaccines10050668.
9
COVID-19 vaccination in patients with immune-mediated inflammatory diseases receiving rituximab: A personalized regimen should be formulated.接受利妥昔单抗治疗的免疫介导性炎症疾病患者的新冠病毒疫苗接种：应制定个性化方案。
J Am Acad Dermatol. 2022 Jul;87(1):e45-e46. doi: 10.1016/j.jaad.2022.02.070. Epub 2022 Mar 29.
10
Overview of infections as an etiologic factor and complication in patients with vasculitides.血管炎患者感染作为病因和并发症概述。
Rheumatol Int. 2022 May;42(5):759-770. doi: 10.1007/s00296-022-05100-9. Epub 2022 Feb 14.
Zotero 插件